Product News Archives | Page 4 of 8 | Aurobindo Pharma USA

Currently Browsing

All Product News

May 17, 2021


Aurobindo Receives FDA Approval for Dorzolamide HCl and Timolol Maleate Ophthalmic Solution, 2%/0.5% (10mL bottles)

East Windsor, N.J. –Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Dorzolamide HCl and Timolol Maleate Ophthalmic Solution, 2% / 0.5% (10 mL bottles). Aurobindo Pharma’s Dorzolamide HCl and Timolol Maleate Ophthalmic Solution, are an AT-rated generic equivalent to the reference listed drug (RLD), […]

April 05, 2021


Aurobindo Receives FDA Approval for Potassium Chloride Extended-Release Tablets USP, 10 mEq, 15 mEq, and 20 mEq

East Windsor, N.J. –Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Potassium Chloride Extended-Release Tablets USP, 10 mEq, 15 mEq, and 20 mEq. Aurobindo Pharma’s Potassium Chloride Extended Release Tablets, are an AB-rated generic equivalent to the reference listed drug (RLD), Potassium Chloride Extended […]

March 29, 2021


Aurobindo Receives FDA Approval for Leflunomide Tablets USP, 10 mg and 20 mg

East Windsor, N.J. –Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Leflunomide Tablets USP, 10 mg and 20 mg. Aurobindo Pharma’s Leflunomide Tablets USP, are an AB-rated generic equivalent to the reference listed drug (RLD), Arava® Tablets marketed by Sanofi-aventis U.S. LLC. Leflunomide Tablets […]

February 18, 2021


Aurobindo Receives FDA Approval for Droxidopa Capsules, 100mg, 200mg, and 300mg

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Droxidopa Capsules, 100mg, 200mg, and 300mg. Aurobindo Pharma’s Droxidopa Capsules, 100mg, 200mg, and 300mg are an AB-rated generic equivalent to the reference listed drug (RLD), Northera® Capsules 100mg, 200mg, and 300mg marketed by Lundbeck NA Ltd.  Droxidopa Capsules are […]

January 25, 2021


Aurobindo received FDA Approval for Tobramycin Inhalation Solution, 300 mg/5 mL

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Tobramycin Inhalation Solution, 300 mg/5 mL. Aurobindo Pharma’s Tobramycin Inhalation Solution, 300 mg/5 mL are an AB-rated generic equivalent to the reference listed drug (RLD), Tobi® Inhalation Solution, 300 mg/5 mL marketed […]

January 04, 2021


Aurobindo Acquires Clorazepate Dipotassium Tablets 3.75mg, 7.5mg and 15mg

East Windsor, N.J. – Aurobindo Pharma Limited has acquired Clorazepate Dipotassium Tablets 3.75mg, 7.5mg and 15mg from Mylan Pharmaceuticals Inc., a Viatris Company. Mylan has agreed to transfer the FDA-approved ANDA for each of these products to Aurobindo Pharma USA, Inc. and Aurobindo will begin to market, distribute, and sell these products as of January 1, […]

December 03, 2020


Aurobindo Receives FDA Approval for Ketorolac Tromethamine Ophthalmic Solution, 0.5%

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Ketorolac Tromethamine Ophthalmic Solution, 0.5%. Aurobindo Pharma’s Ketorolac Tromethamine Ophthalmic Solution, 0.5% are an AB-rated generic equivalent to the reference listed drug (RLD), Acular® Ophthalmic Solution, 0.5% (Allergan, Inc.) Ketorolac Tromethamine Ophthalmic […]

August 14, 2020


Aurobindo Pharma’s JV, Eugia Pharma receives FDA approval for Tamoxifen Citrate Tablets USP, 10 mg and 20 mg

East Windsor, N.J. – Aurobindo Pharma’s JV, Eugia Pharma has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Tamoxifen Citrate Tablets USP, 10 mg and 20 mg. Aurobindo’s  JV, Eugia Pharma Tamoxifen Citrate Tablets USP, 10 mg and 20 mg. are an AB-rated generic equivalent to the reference listed drug (RLD), Nolvadex® Tablets, […]

August 12, 2020


Aurobindo Receives FDA Approval for Methocarbamol Tablets USP, 750 mg

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Methocarbamol Tablets USP, 750 mg. Aurobindo’s Methocarbamol Tablets USP, 750 mg are an AB-rated generic equivalent to the reference listed drug (RLD), Robaxin-750® Tablets of Auxilium Pharmaceuticals, LLC. Methocarbamol Tablets are indicated for: Indicated as an adjunct […]

August 11, 2020


Aurobindo received FDA Approval for Midodrine Hydrochloride Tablets USP, 2.5 mg, 5 mg, and 10 mg

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Midodrine Hydrochloride Tablets USP, 2.5 mg, 5 mg, and 10 mg.  Aurobindo’s Midodrine Hydrochloride Tablets USP, 2.5 mg, 5 mg, and 10 mg, are an AB-rated generic equivalent to the reference listed drug (RLD), ProAmatine Tablets […]

July 31, 2020


Aurobindo Receives FDA Approval for Anastrozole Tablets USP, 1 mg

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Anastrozole Tablets USP, 1 mg. Aurobindo’s Anastrozole Tablets USP, 1 mg are an AB-rated generic equivalent to the reference listed drug (RLD), Arimidex Tablets, 1 mg, of ANI Pharmaceuticals, Inc. Anastrozole Tablets […]

July 31, 2020


Aurobindo Receives FDA Approval for Imatinib Mesylate Tablets 100 mg and 400 mg

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Imatinib Mesylate Tablets, 100 mg and 400 mg. Aurobindo’s Imatinib Mesylate Tablets, 100 mg and 400 mg are an AB-rated generic equivalent to the reference listed drug (RLD), Gleevec Tablets, 100 mg […]